Lizza L. Hendriks

Lizza L. Hendriks

Maastricht, LI, Netherlands

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 187 publications

Concerns Regarding NSCLC Immunoradiotherapy Study Interpretability.

Concerns Regarding NSCLC Immunoradiotherapy Study Interpretability.

Journal: JAMA oncology

Published: August 20, 2026

Bridging evidence and practice: international multidisciplinary consensus on non-metastatic NSCLC.

Bridging evidence and practice: international multidisciplinary consensus on non-metastatic NSCLC.

Journal: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer

Published: May 26, 2026

Targeted therapies in advanced non-small-cell lung cancer: new biomarkers and treatment strategies.

Targeted therapies in advanced non-small-cell lung cancer: new biomarkers and treatment strategies.

Journal: The Lancet. Respiratory medicine

Published: May 26, 2026

Early-stage non-small-cell lung cancer: emerging treatments and evolving challenges.

Early-stage non-small-cell lung cancer: emerging treatments and evolving challenges.

Journal: The Lancet. Respiratory medicine

Published: May 09, 2026

Metastatic Trajectories in Non-Small Cell Lung Cancer Guide Local and Systemic Therapies.

Metastatic Trajectories in Non-Small Cell Lung Cancer Guide Local and Systemic Therapies.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: May 05, 2026

Model-informed approaches to develop drug cost-saving dosing strategies for pembrolizumab.

Model-informed approaches to develop drug cost-saving dosing strategies for pembrolizumab.

Journal: European journal of cancer (Oxford, England : 1990)

Published: April 10, 2026

Prognostic implication of malignant pleural metastases in stage M1a non-small cell lung cancer in a real-world Dutch cohort receiving chemotherapy and/or immunotherapy.

Prognostic implication of malignant pleural metastases in stage M1a non-small cell lung cancer in a real-world Dutch cohort receiving chemotherapy and/or immunotherapy.

Journal: The European respiratory journal

Published: March 16, 2026

First-Line Integration of Local Ablative Therapy With EGFR Tyrosine Kinase Inhibitors in Advanced EGFR+ NSCLC: A Systematic Review and Meta-Analysis.

First-Line Integration of Local Ablative Therapy With EGFR Tyrosine Kinase Inhibitors in Advanced EGFR+ NSCLC: A Systematic Review and Meta-Analysis.

Journal: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer

Published: March 01, 2026

Development of a rapid ex vivo tumor platform for drug response prediction in lung cancer.

Development of a rapid ex vivo tumor platform for drug response prediction in lung cancer.

Journal: NPJ precision oncology

Published: February 23, 2026

KRAS G12C inhibitors versus chemotherapy in second line and beyond in adults with advanced or metastatic non-small cell lung cancer (NSCLC) harbouring the KRAS G12C mutation.

KRAS G12C inhibitors versus chemotherapy in second line and beyond in adults with advanced or metastatic non-small cell lung cancer (NSCLC) harbouring the KRAS G12C mutation.

Journal: The Cochrane database of systematic reviews

Published: February 17, 2026

Radiotherapy has a role to play in patients with EGFR-mutated non-small-cell lung cancer in first-line treatment.

Radiotherapy has a role to play in patients with EGFR-mutated non-small-cell lung cancer in first-line treatment.

Journal: The Lancet. Oncology

Published: February 05, 2026

Stereotactic Body Radiotherapy Without Systemic Therapy for Oligometastatic Cancer: A Systematic Review and Meta-Analysis.

Stereotactic Body Radiotherapy Without Systemic Therapy for Oligometastatic Cancer: A Systematic Review and Meta-Analysis.

Journal: JAMA network open

Published: February 03, 2026

Showing 1-12 of 187

Last Updated: 09/26/2026